Title: Demethylation and upregulation of an oncogene post hypomethylating treatment

Authors: Yao-Chung Liu[1,2,3,4°], Emiliano Fabiani[5°], Junsu Kwon[6°], Chong Gao[1], Giulia Falconi[5], Lia Valentini[5], Carmelo Gurnari[5], Yanjing V. Liu[6], Adrianna I. Jones[7], Junyu Yang[1], Henry Yang[6], Julie A. I. Thoms[8], Ashwin Unnikrishnan[9], John E. Pimanda[8,9,10], Rongqing Pan[11], Maria Teresa Voso[5*], Daniel G. Tenen[6,7*], Li Chai[1*]

Affiliations:

[1]Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA

[2]Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

[3]Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

[4]Program in Molecular Medicine, School of Life Science, National Yang-Ming University, Taipei, Taiwan

[5]Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy

[6]Cancer Science Institute of Singapore, National University of Singapore, 117599, Singapore

[7]Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115 USA

[8]School of Medical Sciences and Lowy Cancer Research Centre, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia

[9]Prince of Wales Clinical School and Lowy Cancer Research Centre, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia

[10]Department of Haematology, Prince of Wales Hospital, Randwick, NSW 2031, Australia

[11] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115

°These authors contibute equally to this work

*Co-corresponding authors: lchai@bwh.harvard.edu, daniel.tenen@nus.edu.sg, and voso@med.uniroma2.it

The authors have declared that no conflict of interest exists.

Abstract

Background: While hypomethylating agents (HMA) are currently used to treat myelodysplastic syndrome (MDS) patients, their effects on reactivation and/or upregulation of oncogenes are generally not well elucidated. SALL4 is a known oncogene that plays an important role in MDS. In this study, we examined the relationship between SALL4 methylation and expression, and evaluated changes of SALL4 expression and their prognostic value in MDS patients undergoing HMA treatment.

Methods: No/low-SALL4 expressing leukemic K562 and HL-60 cell lines were used to study the relationship between SALL4 methylation and expression. Additionally, paired bone marrow (BM) samples from MDS patients on the BMT-AZA trial (EudraCT number 2010-019673-15), collected before and after four cycles of azacytidine (AZA) treatment, were used to explore the relationship between changes in SALL4 expression, treatment response and clinical outcome.

Findings: In cell lines, we identified that demethylation of a critical CpG region was associated with increased SALL4 expression, and HMA treatment led to demethylation of this region and upregulation of SALL4. In MDS patients, we noted SALL4 upregulation after four cycles of AZA treatment in 40% of the cases. Significantly, patients in the responder group with SALL4 upregulation had the worst outcome.

Interpretation: This is the first study on demethylation and upregulation of the SALL4 oncogene after HMA treatment in MDS patients, and its clinical impact on treatment response and outcome. Our data indicate that MDS patients receiving HMA treatment should be monitored for SALL4 upregulation for poor outcome, especially in HMA responders.

Funding: Myeloid Neoplasms Research Venture AIRC MYNERVA, National Institutes of Health;

Singapore Ministry of Health's National Medical Research Council; Leukemia and Lymphoma Society and Xiu Research Fund.

Research in context

Evidence before this study: We searched PubMed on May 9, 2020, with no starting date limitations, using the search terms “hypomethylating agent”, “prognosis”, “myelodysplastic syndrome”, “oncogene” and “demethylation”. Our literature search did not show any report on oncogene demethylation and/or re-activation as a result of hypomethylating agent (HMA) treatment for myelodysplastic syndrome (MDS). While HMAs are currently used to treat MDS patients, their effects on reactivation and/or upregulation of oncogenes are generally not well elucidated. In addition, the survival after HMA in 'real-world' high risk (HR)-MDS/low-blast count acute myeloid leukemia (AML) was lower than the expected overall survival (OS) in clinical trials, and the outcome after HMA failure was less than 6 months. To date, there is no treatment available to improve OS after HMA failure.

Added value of this study: SALL4 is a known oncogene that plays an important role in MDS. In this study, we examined the relationship between SALL4 methylation and expression, and evaluated changes of SALL4 expression and their prognostic value in MDS patients undergoing HMA treatment. No/low-SALL4 expressing leukemic K562 and HL-60 cell lines were used to study the relationship between SALL4 methylation and expression. Additionally, paired bone marrow (BM) samples from MDS patients on the BMT-AZA trial (EudraCT number 2010-019673-15), collected before and after four cycles of azacytidine (AZA) treatment, were used to explore the relationship between changes in SALL4 expression, treatment response and clinical outcome.

Implications of all the available evidence: In cell lines, we identified that demethylation of a critical CpG region was associated with increased SALL4 expression, and HMA treatment led to demethylation of this

region and upregulation of SALL4. In MDS patients, we noted SALL4 upregulation after four cycles of AZA treatment in 40% of the cases. Significantly, patients in the responder group with SALL4 upregulation had the worst outcome. Our data indicate that MDS patients receiving HMA treatment should be monitored for SALL4 upregulation for poor outcome, especially in HMA responders.

Key words: SALL4, Myelodysplastic syndrome, Hypomethylating treatment resistance, Azacytidine, Prognosis

Introduction

Myelodysplastic syndrome (MDS) comprises heterogeneous myeloid disorders characterized by cytopenias and dysplasia in peripheral blood and bone marrow (BM), with ineffective hematopoiesis and a variable risk of leukemic transformation.[1,2] The revised International Prognostic Scoring System (IPSS-R) provides a reliable estimation of the risks of leukemic transformation, progression, and death.[3,4] In addition, MDS is characterized by high genetic heterogeneity with rare cases bearing a single gene mutation, and often with a combination of mutations in splicing factors (e.g., *SF3B1, SRSF2, U2AF1, ZRSR2*; seen in approximately 40–60% of patients) and/or epigenetic regulators (e.g., *TET2, ASXL1, DNMT3A, EZH2, IDH1, IDH2*; observed in approximately 40–50%) %) in most patients.[5]

For high-risk (HR) patients, those that are elderly or unfit to receive chemotherapy, hypomethylating agent (HMA) therapy is the first-line treatment, and also used as a bridge to transplant in younger patients.[6,7] The optimal timing to assess cytidine nucleoside analog azacytidine (AZA) response is after four to six cycles of treatment, and overall survival (OS) was reported to be prolonged in two thirds of patients receiving at least four cycles of treatment.[7,8] Although continuous AZA therapy in responders was reported to be beneficial to improve patients' clinical parameters, the survival after AZA in 'real-world' HR-MDS/low-blast count acute myeloid leukemia (AML) was lower than the expected OS in clinical trials,[7] and the outcome after AZA failure was less than 6 months.[9] To date, there is no treatment available to improve OS after HMA failure. Therefore, the key is to identify biologic or molecular predictor(s) that could guide the clinician to decide on the timing of HMA-based combination regimens, which will hopefully improve clinical outcomes in patients

with first-line HMA monotherapy. Despite the known mode of action of the drugs, there seems to be little correlation between the degree of demethylation following HMA and hematologic response.[10] Furthermore, it has been hypothesized that global HMA treatment not only contributes to the demethylation of tumor suppressor genes but can also induce demethylation of oncogenes[11]. Therefore, there is a potential risk of reactivation and/or upregulation of oncogenes by HMA treatment, which has not been well understood. To fill this knowledge gap, we used the known oncogene SALL4 as an example to examine the effects of HMA on reactivation and/or upregulation of oncogenes, and its related clinical impact on treatment response and overall outcomes.

Spalt-like transcription factor 4 *(SALL4)* plays an essential role in MDS and AML leukemogenesis[12,13] and tumorigenesis in various solid tumors.[14-16] SALL4 is reactivated or aberrantly expressed in a multitude of cancers; and identified by meta-analysis as a promising poor prognostic factor implicated in cancer recurrence.[17] In hematological malignancies, SALL4 is aberrantly expressed in HR-MDS[18], AML[13,19], and precursor B-cell lymphoblastic leukemia/lymphoma.[20] In a murine model with constitutive SALL4 expression, mice developed MDS-like features and subsequently leukemic transformation through activation of the Wnt/beta-catenin pathway.[21] These mice also demonstrated impairment of DNA damage repair linked to the Fanconi anemia pathway.[22] In MDS patients, the levels of SALL4 were high in HR-IPSS and positively correlated with blast count and high-risk karyotypes. Notably, the expression level of SALL4 significantly increased in MDS/AML transformation and decreased following effective therapy.[18] Moreover, aberrant hypomethylation of *SALL4* at diagnosis was frequent in HR-MDS patients (14% in Low/Int-1

versus 39% in Int-2/High), and the survival of the *SALL4*-hypomethylated group was shorter than that of *SALL4*-methylated group.[23] However, the effect of HMA on SALL4 expression and its clinical implications for MDS/AML patients are unknown.

Using a novel CRISPR-DNMT1-interacting RNA (CRISPR-DiR) approach, we first identified and demethylated the CpG island critical for SALL4 expression. We then evaluated the effects of HMA treatment on the methylation status and expression of SALL4 in cell lines with none/low SALL4 expression. We then retrospectively analyzed SALL4 expression and clinical survival of 25 MDS patients with BM samples before and after four cycles of AZA treatment, from a cohort of 37 patients enrolled in the BMT-AZA trial. A second cohort of 14 patients after six cycles of AZA treatment was analyzed as well.

Patients and methods

Cell culture and treatment protocol

The K562 and HL-60 human leukemia cell lines were purchased from the ATCC and cultured in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics (penicillin-streptomycin 100U/100 μg/mL) and maintained in an incubator with 5% CO2 atmosphere at 37°C. Based on previous publications[24], 100nM, 250nM, and 500nM 5-aza-2'-deoxycytidine (decitabine, DAC) daily was used to treat K562 and HL-60 cells for 5 days. Before adding new DAC or DMSO treatment, cells were washed with ice-cold PBS at 24-hour intervals. Cells were collected on day 5 for measuring SALL4 levels using droplet digital polymerase chain reaction (ddPCR) and western blot as well as methylation studies. For cell growth experiments after drug

treatments, HL-60 cells were treated with either DMSO, 250nM DAC, or 20nM venetoclax, or both. Viable cell numbers were calculated compared to DMSO treatment on day 2, 4, 6, and 8.

Patients and sample collection

BM samples were obtained from 37 newly diagnosed MDS patients enrolled in the BMT-AZA trial (EudraCT number 2010-019673-15). [25,26] $CD34^-$ (n = 10) and $CD34^+$ (n = 5) BM mononuclear cells (BM-MNCs) from healthy donors were used as control cohorts. In 37 MDS patients, 25 patients had paired BM samples collected before and after four AZA cycles. BM-MNCs were isolated by Ficoll gradient centrifugation using Lympholyte-H (Cedarlane, Ontario, Canada), according to the manufacturer's instructions. MDS diagnoses were according to the 2008 World Health Organization (WHO) classification.[27] All 25 studied patients received at least four cycles of AZA treatment. Other clinical characteristics including age at diagnosis, sex, IPSS, WHO-Classification Based Prognostic Scoring System (WPSS), response after four cycles of AZA treatment, peripheral blood counts, BM blasts, and cytogenetics were also reviewed. The definition of first response follows the International Working Group (IWG) criteria.[28] In the study, responders included patients achieving complete remission (CR), partial remission (PR), and hematologic improvement (HI), whereas nonresponders included those patients with stable disease (SD) and progressive disease (PD).

Real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)

Total RNA was extracted with Trizol reagent (Invitrogen) according to the manufacturer's instructions and

treated with DNase. The RNA concentration was measured with ultraviolet spectrophotometry. Reverse transcription and PCR were performed using the iScript One-Step RT-PCR Kit with SYBR Green (Bio-Rad, Hercules, CA, USA; catalog no. 170-8893). Triplicate reactions were run for each gene. The expression level was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). For each sample, an amplification plot and corresponding dissociation curves were examined. Relative quantification analysis was performed using the comparative CT method ($2^{-\Delta\Delta CT}$). SALL4 upregulation ($SALL4^{up}$) and downregulation ($SALL4^{down}$) between diagnosis and completion of 4 cycles of AZA treatment (t0 versus t4) were defined as 2-fold. The formula used to determine fold change is as follows: $2^{-\Delta\Delta CT} = 2^{-[\text{ t4 CT (SALL4 after AZA) – t4 CT (GAPDH)] –[t0 CT (SALL4 at diagnosis)–t0 CT (GAPDH)]}}$, a scale of 1 to infinity and a scale of less than -1, were used to define $SALL4^{up}$ or $SALL4^{down}$ respectively. The sequences of primers for genes tested as follows: *SALL4* (*SALL4* exon3/4 span), forward primer 5′-AAGGCAACTTAAAGGTTCACTACA-3′, reverse primer 5′-GATGGCCAACTTCCTTCCA-3′; *SALL4A*-specific, forward primer 5′-TGATCCCAACGAATGTCTCA-3′, reverse primer 5′-CCCAAGGTGTGTCTTCAGGT-3′; *SALL4B*-specific, forward primer 5′-AAGCACAAGTGTCGGAGCA-3′, reverse primer 5′-GTGCAGCCATGTTGCTTG-3′; *GAPDH*, forward primer 5′-GAAGGTGAAGGTCGGAGTCAAC-3′, reverse primer 5′-TGGAAGATGGTGATGGGATTTC-3′.

Western blot

Western blot was performed according to standard protocol. The following antibodies were used for western blotting: SALL4 (ab29112, Abcam), and GAPDH (Santa Cruz, sc-25778). The dilution ratio of SALL4

antibody was 1:1000.

Study endpoints and statistical analysis

Clinical characteristics and mutational profiling are presented as the total number (*n*) and proportion (%). Data are presented as medians and interquartile ranges (IQR) for skewed data. The Fisher exact test or chi-squared test, as appropriate, were used to compare categorical variables, whereas continuous variables were compared using the Wilcoxon rank-sum test. Fold change of SALL4 mRNA levels between responders and nonresponders was compared using the Mann-Whitney U test. Progression-free survival (PFS) was defined as the time from AZA treatment to disease progression or death from the treatment, whereas OS was defined as time from AZA treatment to death. OS and PFS were analysed using the Kaplan–Meier product–limit method with censoring for the patients who did not progress or die during the treatment period. A log–rank test was used to compare survival curves for statistical significance. Hazard ratios (HRs) and the 95% confidence interval (CI) were calculated using Cox proportional-hazards model. All prognostic factors with $p < 0.1$ in the univariate model were further entered into the multivariate analysis. All statistical testing was performed using 2-tailed tests; $p < 0{\cdot}05$ was considered statistically significant. All analyses were performed using SPSS statistical software, version 22 (SPSS, Chicago, IL).

Results

Demethylation of a critical CpG region leads to upregulation of SALL4

The SALL4 5'UTR – exon 1 – intron 1 region is differentially methylated in K562-induced pluripotency reprogrammed cells.[29] To define the correlation between methylation of this region and SALL4 expression,

we applied the CRISPR-DiR technique, a novel approach to induce locus-specific demethylation by blocking DNMT1 activity in HL-60 cells (low/no SALL4 expression).[30] Methylation of this CpG region was monitored in HL-60 cells with specific CRISPR-DNMT1-interacting RNA (CRISPR-DiR) induction (Figure 1A). Upon transduction of HL-60 cells with sgSALL4_1, significant demethylation changes were observed after 8 days (Figure 1B) as well as increased SALL4 transcript levels (Figure 1C). This suggests that demethylation of this region can lead to upregulation of SALL4.

HMA treatment can lead to demethylation and upregulation of SALL4

We then tested whether SALL4 could be upregulated by HMAs. Using the same wildtype HL-60 cells, we first evaluated the dynamics of SALL4 levels through a cycle of 5-aza-2'-deoxycytidine (DAC) treatment using a dosage range from 100nM to 500nM. The number of mRNA copies per cell (by ddPCR) and protein (by western blot) for SALL4 was measured at day 5. We noticed dose dependent upregulation of SALL4 RNA expression at day 5 (Figure 1D & E). We then examined the methylation status of the SALL4 5'UTR-Exon 1-Intron 1 CpG island region after 250nM DAC treatment, and found this region was demethylated in HL-60 cells, in accordance with our CRISPR-DiR result (Figure 1F). Similar results were also observed in another SALL4-low leukemic cell line, K562 cells (Figure 1 G, H&I).

Changes in SALL4 expression in MDS patients receiving 4 cycles of HMA

Next, we evaluated the impact of HMA treatment on primary MDS patients. Consistent with our observation in cell lines, SALL4 mRNA expression was upregulated at the end of the first cycle of HMA in MNCs

isolated from the peripheral blood of three newly diagnosed MDS patients, one treated with AZA and two with DAC (Fig. S1).

To further evaluate the impact of HMA on SALL4 expression after 4 cycles of HMA treatment. To this end, we first measured baseline SALL4 expression at diagnosis from BM-MNCs of MDS patients prior to AZA treatment. In 37 MDS patients, 33 were categorized as high/intermediate-2 risk according to IPSS, whereas 2 patients were intermediate-1/low risk. The risk of the remaining two patients was unknown due to unavailable cytogenetics. Levels of SALL4 mRNA were significantly higher in 37 MDS patients ($p = 0{\cdot}002$) and in healthy $CD34^+$ ($p = 0{\cdot}002$) compared to $CD34^-$ cells from healthy donors (Figure 2A), similar to what has been reported previously.[18] Among the 37 enrolled MDS patients, there were 25 patients with available paired BM samples at diagnosis and after 4 cycles of AZA. Of these 25 patients, 48% were defined as responders, with 36% achieving CR, 8% PR, and 4% HI, respectively. These 25 patients were then stratified according to the fold change in SALL4 mRNA expression pre- and post- AZA treatment (Fig. S2). A waterfall plot depicting fold changes in SALL4 mRNA levels clearly demonstrated that patients separated into two distinct groups based on SALL4 expression (Figure 2B). Ten out of the twenty-five patients (40%) had ≥ 2 -fold increase in SALL4 expression ($SALL4^{up}$) whereas fifteen patients (60%) had ≥ 2- fold decrease in SALL4 expression ($SALL4^{down}$) after 4 cycles of AZA treatment. The median log_2 fold change for $SALL4^{up}$ was 2·78 (IQR: 2·15-5·65), whereas $SALL4^{down}$ was -2·25 with IQR from -1·26 to -4·45. We also evaluated the methylation status of the patient samples. In four patients with increased SALL4 expression, we noticed decreased methylation at this critical CpG region (Figure 2C). Conversely,

we did not observe substantial changes in the methylation profiles within the 5' UTR – exon 1 – intron 1 region of the patients with repressed SALL4 expression post-AZA treatment (Fig. S3).

Poor outcome in MDS responders with SALL4 upregulation post HMA treatment

In the MDS patient cohort (n = 25), SALL4 upregulation was found in five patients in both the responder (n = 12) and non-responder (n = 13) groups, while seven and eight patients demonstrated SALL4 downregulation in the responder and non-responder groups, respectively. There was no significant difference in fold change of SALL4 mRNA between responders and non-responders (Fig. S4). However, surprisingly, when compared between the SALL4^{up} (n = 10) and SALL4^{down} (n = 15) groups, there was a trend towards a difference in PFS (p = 0·09, Figure 3A) and a significant OS difference (p = 0·03, median: 13·8 months in the SALL4 upregulated vs. not reached in the SALL4 downregulated, Figure 3B), indicating that SALL4 upregulation is associated with decreased survival. Demographic and clinical-biological characteristics between the SALL4^{up} and the SALL4^{down} patients (median age of 60 years for both groups) were compared, and the only significant difference was gender, with more males in the upregulated group. The IPSS risk, WPSS risk, peripheral blood counts, categories of cytogenetics, and mutational profiles were not different between these two groups (Table S1). In both groups, approximately 70% of patients subsequently received allogeneic stem cell transplantation.

Intriguingly, based on the categories of clinical response and SALL4 expression change, we could further divide these patients into four subgroups, including responder/SALL4^{down}, non-responder/SALL4^{down},

responder/SALL4^{up}, and non-responder/SALL4^{up}. There was significantly better PFS and OS in the responder/SALL4^{down} group than in the other three subgroups (p = 0·03 in PFS; p = 0·04 in OS). The median survival in PFS or OS was not reached in the responder/SALL4^{down} subgroup. But most strikingly, in the responder/SALL4^{up} group (n = 5), the median survival in PFS and OS was a dismal 7·9 months and 8·0 months, respectively (Figure 3C and 3D).

Since genetic mutations, including epigenetic factors such as DNMT3A, IDH1, IDH2, and TET2 are common in MDS patients, we questioned whether the up or down regulation of SALL4 in patients post-AZA treatment was related to their pre-existing mutation status. The impact of AZA treatment and somatic mutations on PFS and OS in the whole cohort of the BMT-AZA trial has been reported.[25,26] Here, we correlated the BM-MNCs mutational profile of the 25 patients selected for this study with SALL4 expression. Common somatic mutations in 30 genes, known to be frequently mutated in MDS patients, are reported below. At the diagnosis of MDS, we identified at least one mutation with more than 1% VAF in 22 out of 25 patients (88%). The median number of mutated genes was three per patient (range: 0-6). The most commonly mutated genes in this population were: *ASXL1* (36%), *TET2* (28%), *RUNX1* (24%), *SETBP1* (24%), *ZRSF2* (20%), *TP53* (20%), *SRSF2* (16%), and *DNMT3A* (16%). Ten out of 22 patients had more than one gene mutation (Fig. S5)

At median follow-up of 14·1 months (IQR: 9·0–20·4) after starting AZA, we further conducted Cox proportional - hazards model analysis for prognostic factors on OS based on characteristics at diagnosis,

mutational profile with presentation in more than four patients, and SALL4 expression changes. In multivariate analysis for OS, only SALL4^{up} (HR 6·48; 95% CI, 1·06 to 39·67; p = 0·04) and *RUNX1* mutation (HR 10·66; 95% CI, 1·25 to 90·72; p = 0·03) were independent negative predictors for OS (Table 1).

Combination therapy as an alternative treatment after SALL4 induction

We next tested the hypothesis that additional SALL4-targeting drugs should be administered to MDS patients undergoing monotherapy with HMA once SALL4 is upregulated to achieve better disease control, and hopefully better survival rates. In our previous studies, we reported that SALL4 could upregulate BCL2 in leukemic cells.[22] Venetoclax, a FDA approved BCL2 inhibitor, is currently being used in the clinic for hematologic malignancies. We decided to evaluate whether combination therapy using low dose DAC and venetoclax has a better therapeutic effect on leukemic cells than monotherapy with either DAC or venetoclax alone. HL-60 cells were treated with DAC monotherapy or combination therapy (DAC+venetoclax) (Figure 3E). Compared to the DMSO control, monotherapy using either DAC dosage at 250nM, or venetoclax at 20nM, had no therapeutic effect on HL-60 cells; In contrast, DAC at 250nM in combination with venetoclax at 20nM resulted in a significant decrease in leukemic cell numbers compared to either DAC or venetoclax monotherapy at the same dose, suggesting more effective therapy. We therefore propose to add venetoclax as SALL4 targeting agents to the HMA monotherapy as an alternative method to achieve improved therapeutic effect and survival.

Discussion

SALL4 is an oncogene that plays an important role in MDS and AML.[12,13,18,19,22] The level of SALL4 was reported as a molecular biomarker for diagnosis and prognosis of AML and for diagnosis of MDS.[12,13,21] High levels of SALL4 transcripts and hypomethylation of *SALL4* were also significantly found in patients with higher IPSS or WPSS risk.[18] Hypomethylation was recognized as a probable mechanism for aberrant high *SALL4* expression in MDS patients, but the effect of HMA on SALL4 expression has not been reported yet. Using a novel CRISPR-DiR approach, we have identified a critical CpG island responsible for SALL4 expression, and HMA treatment can lead de-methylation of this region and upregulation of SALL4 (Figures 1 and 2).

In our cohort of MDS patients (n = 25), we observed that after four cycles of AZA treatment, 40% of our patients (n = 10) were SALL4^{up} while 60% (n = 15) were SALL4^{down}. While the fold change of SALL4 expression was not significantly different between clinical responders and non-responders, it was surprising to note the strikingly poor outcome of responders who have upregulated SALL4 (Figure 3C and 3D). In general, the responder group of MDS patients are considered to have a good outcome based on their clinical parameters after HMA treatment. However, the results from our study suggests that a more cautious approach is needed. HMA monotherapy can activate or upregulate oncogenes. In the case of SALL4, if SALL4 is upregulated, clinicians should not rely on clinical parameters to predict the outcome of their patients. Instead, we propose that MDS patients on HMA therapy should be monitored for SALL4 expression in addition to traditional clinical parameters. If SALL4 expression is upregulated, alternative

therapy that directly or indirectly mitigates SALL4 expression should be added to the treatment plan. Since the function of SALL4 is linked to BCL2[22], we further demonstrated that low dose DAC can be used in combination with venetoclax, and are more effective than DAC monotherapy in reducing leukemia cell numbers (Figure 3E).

In conclusion, this is the first report of HMA treatment inducing upregulation of an oncogene that is associated with poor outcome in HR-MDS patients. Our observation on SALL4^{up} responders suggests that this group needs close monitoring. Alternative combination therapy, including those targeting SALL4, should be added to the treatment plan for at-risk patients. Our studies lay the foundation for future clinical trials combining HMA and venetoclax in SALL4^{up} MDS patients.

Authors' contributions: Yao-Chung Liu and Li Chai generated and helped conceive the study design, figures, tables, and manuscript. Emiliano Fabiani and Maria Teresa Voso collected and analysed experimental patients' data. Yao-Chung Liu and Henry Yang performed statistical analyses. Junsu Kwon performed the CRISPR-DiR, drug treatment experiments of K562 and HL-60 cell lines, ddPCR, CRISPR-DiR, and methylation, and generated figures. Yanjing Liu assisted in the CRISPR-DiR experiments. Giulia Falconi cooperated in the somatic screening (NGS) of the patient cohort. Lia Valentini performed all the expression experiments (Q-PCR). Carmelo Gurnari kindly reviewed the clinical data and took a part in samples selection. Adrianna I. Jones and Junyu Yang helped edit the manuscript and performed part of the leukemic cell line experiments. Julie Thoms, Ashwin Unnikrishnan, John Pimanda, Yao-Chung Liu,

Emiliano Fabiani, Junsu Kwon, Chong Gao, Maria Teresa Voso, Daniel G Tenen, and Li Chai participated in manuscript preparation. All authors participated in data interpretation and critical review of the final paper and submission.

Declaration of Interests: The authors declare no competing financial interests.

Acknowledgements: This study was supported by AIRC 5x1000 call "Metastatic disease: the key unmet need in oncology" to MYNERVA project, #21267 (Myeloid Neoplasms Research Venture Airc). A detailed description of the MYNERVA project is available at http://www.progettoagimm.it.This work was also by Singapore Ministry of Health's National Medical Research Council (Singapore Translational Research (STaR) Investigator Award, D.G.T.; NMRC/OFIRG/0064/2017, W.L.T; LCG17MAY004, W.L.T.; NMRC/TCR/015-NCC/2016, W.L.T.); National Research Foundation Singapore (NRF-NRFF2015-04 Grant, W.L.T.) and the Singapore Ministry of Education under its Research Centres of Excellence initiative; Singapore Ministry of Education Academic Research Fund Tier 3, grant number MOE2014-T3-1-006 (D.G.T); NIH/NCI Grant R35CA197697 and NIH/NHLBI P01HL131477 (D.G.T); as well as NIH/NHLBI Grant P01HL095489 (L.C.); LLS Grant P-TRP-5854-15 and Xiu research fund (L.C); National Health and Medical Research Council of Australia (JEP: APP1024364, APP1043934, APP1102589; AU: APP1163815) and Leukemia & Lymphoma Society USA Translational Program Grant 6589-20 (AU).

References

1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med 2005; **352**(6): 536-8.
2. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; **126**(1): 9-16.
3. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; **28**(2): 241-7.
4. Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica 2014; **99**(6): 956-64.
5. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; **122**(22): 3616-27; quiz 99.
6. Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J 2018; **8**(5): 47.
7. Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol 2018; **181**(6): 803-15.
8. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; **117**(12): 2697-702.
9. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; **29**(24): 3322-7.
10. Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica 2014; **99**(4): 613-9.
11. Fabiani E, Leone G, Giachelia M, et al. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010; **51**(12): 2275-84.
12. Gao C, Kong NR, Chai L. The role of stem cell factor SALL4 in leukemogenesis. Crit Rev Oncog 2011; **16**(1-2): 117-27.
13. Ma Y, Cui W, Yang J, et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 2006; **108**(8): 2726-35.
14. Kobayashi D, Kuribayshi K, Tanaka M, Watanabe N. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol 2011; **38**(4): 933-9.
15. Liu A, Cheng L, Du J, et al. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol 2010; **34**(5): 697-706.
16. Yong KJ, Gao C, Lim JS, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013; **368**(24): 2266-76.
17. Shen H, Li L, Wang D, et al. Higher expression of SALL4 predicts poor cancer prognosis: A meta-analysis. Cancer Biomark 2017; **19**(4): 365-73.
18. Wang F, Guo Y, Chen Q, et al. Stem cell factor SALL4, a potential prognostic marker for

myelodysplastic syndromes. J Hematol Oncol 2013; **6**(1): 73.
19. Li A, Yang Y, Gao C, et al. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. J Clin Invest 2013; **123**(10): 4195-207.
20. Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol 2006; **19**(12): 1585-92.
21. Shuai X, Zhou D, Shen T, et al. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes. Cancer Genet Cytogenet 2009; **194**(2): 119-24.
22. Wang F, Gao C, Lu J, et al. Leukemic survival factor SALL4 contributes to defective DNA damage repair. Oncogene 2016; **35**(47): 6087-95.
23. Lin J, Qian J, Yao DM, et al. Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome. Leuk Res 2013; **37**(1): 71-5.
24. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics 2013; **5**(1): 3.
25. Falconi G, Fabiani E, Piciocchi A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia 2019; **33**(3): 785-90.
26. Voso MT, Leone G, Piciocchi A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol 2017; **28**(7): 1547-53.
27. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; **114**(5): 937-51.
28. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; **108**(2): 419-25.
29. Tatetsu H, Kong NR, Chong G, Amabile G, Tenen DG, Chai L. SALL4, the missing link between stem cells, development and cancer. Gene 2016; 584(2): **111**-9.
30. Di Ruscio A, Ebralidze AK, Benoukraf T, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature 2013; **503**(7476): 371-6.

Figure Legends

Figure 1. Demethylation of a critical CpG island and expression of SALL4 gene in leukemic cells treated with CRISPR-DiR and HMA. (A) Schematic of the CpG region within the SALL4 5' UTR – exon 1 – intron 1 region. (B) Bisulfite sequencing after CRISPR-DiR of HL60 cells transduced with either a non-targeting negative control guide RNA (DiR_NT) or a targeting guide RNA (sgSALL4_1) leading to demethylation (DiR_SALL4). (C) SALL4 transcript (copies per cell assessed by ddPCR) upregulation in HL-60 cells treated with CRISPR-DiR; (D) SALL4 copies per cell by ddPCR in HL-60 cells treated with DAC for 3 days; (E) Western blot in HL-60 cells treated with DAC; (F) Methylation profiling in HL-60 cells untreated (HL60_NT) versus treated with 250 nM DAC (HL60_250); (G) SALL4 transcripts (copies per cell assessed by ddPCR) in K562 cells treated with DAC; (H) Western blot in K562 cells treated with DAC; (I) Methylation profiling in K562 cells treated with DAC.

Figure 2. Expression changes in SALL4 mRNA in 37 patients at MDS diagnosis and 25 patients with paired BM-MNC samples before and after 4 cycles of AZA treatment. (A) Log_2 fold change of SALL4 in 37 MDS patients at diagnosis; (B) Waterfall plot of log_2 fold change of SALL4 in 25 patients; (C) Methylation changes after 4 cycles of AZA treatment in 4 patients. t(0) is baseline, t(4) is after 4 cycles of treatment.

Figure 3. Survival based on the change of SALL4 expression and clinical response. (A) Progression-free survival (PFS) between $SALL4^{up}$ and $SALL4^{down}$; (B) Overall survival (OS) between $SALL4^{up}$ and $SALL4^{down}$; (C) PFS based on treatment response and SALL4 expression change; (D) OS based on

treatment response and SALL4 change. (E) Effects of DAC monotherapy or combination therapy with venetoclax on HL60 cell viability.

Figure 1


A
5'
3'
Exon 1
Intron 1
Exon 4
ATG
CpG# 1
10
20
30
B
DiR_NT
DiR_SALL4
CpG# 1 5 10 15 20 25 30
Methylation 0%
100%
C
Copies per Cell
10
8
6
4
2
0
**
NT
sgSALL4
D
Copies per Cell
10000
1000
100
10
1
**
**
β-actin
DMSO
100
250
500
Decitabine Concentration(nM)
E
SALL4
β-actin
0 100 250 500 (nM)
F
HL60_NT
HL60_250
CpG# 1 5 10 15 20 25 30
Methylation 0%
100%
G
Copies per Cell
1000
100
10
1
*
**
β-actin
DMSO
100
250
500
Decitabine Concentration(nM)
H
SALL4
β-actin
0 100 250 500 (nM)
I
K562_NT
K562_250
CpG# 1 5 10 15 20 25 30
Methylation 0%
100%

Figure 2


A
p=0.17
p=0.002
p=0.002
SALL4 relative expression (Fold ΔCt*10000)
150
100
50
0
CD34⁻
CD34⁺
MDS
CR
PR
HI
SD
PD
B
SALL4 upregulation
SALL4 downregulation
Log2 Fold Change of SALL4 mRNA (t4 vs t0)
10.00
8.00
6.00
4.00
2.00
0.00
-2.00
-4.00
-6.00
-8.00
-10.00
Patient ID
C
pt 21 t(0)
pt 21 t(4)
pt 23 t(0)
pt 23 t(4)
pt 17 t(0)
pt 17 t(4)
pt 24 t(0)
pt 24 t(4)
CpG#
Methylation 0%
100%
D
pt 3 t(0)
pt 3 t(4)
pt 4 t(0)
pt 4 t(4)
pt 1 t(0)
pt 1 t(4)
CpG#
Methylation 0%
100%

Figure 3


A
Sall4 downregulated
Sall4 upregulated
PFS probability
n =15
n =10
p =0.09
Months
Number at risk
Sall4down 15 11 6 2 1
Sall4up 10 6 2 0 0
B
Sall4 downregulated
Sall4 upregulated
OS probability
n =15
n =10
p =0.03
Months
Number at risk
Sall4down 15 12 6 2 1
Sall4up 10 6 2 0 0
C
Responder with Sall4down
Responder with Sall4up
Nonresponder with Sall4down
Nonresponder with Sall4up
PFS probability
n =7
n =5
n =8
n =5
p =0.03
Months
Number at risk
Responder-Sall4down 7 7 3 2 1
Responder-Sall4up 5 2 0 0 0
Nonresponder-Sall4down 8 4 3 0 0
Nonresponder-Sall4up 5 4 2 0 0
D
Responder with Sall4down
Responder with Sall4up
Nonresponder with Sall4down
Nonresponder with Sall4up
OS probability
n =7
n =8
n =5
n =5
p =0.04
Months
Number at risk
Responder-Sall4down 7 7 4 2 1
Responder-Sall4up 5 2 0 0 0
Nonresponder-Sall4down 8 5 3 0 0
Nonresponder-Sall4up 5 4 2 0 0
E
250nM Decitabine
20nM Venetoclax
Sample collection
Day: 0 1 2 3 4 5 6 7 8
Cell Number
Days After Treatment
DMSO
DAC 250nM
Vene 20nM
DAC + Vene
**
***